Muzastotug (ADG126), an Anti-CTLA-4 SAFEbody® in Combination with pembrolizumab showed 33% overall response rate in microsatellite stable colorectal cancer Four confirmed partial responses out of twelve patients with 20 mg/kg loading dose followed by 10 mg/kg Q3W + pembrolizumab No Grade 4/5 treatment related adverse events were observed and no discontinuations occurred to date SAN DIEGO and SUZHOU, China, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the ...

Core Insights - Adagene Inc. is set to present updated clinical data for its drug ADG126 in microsatellite stable colorectal cancer (MSS CRC) at the ASCO Gastrointestinal Cancers Symposium on January 25, 2025 [1][2] Group 1: Clinical Study Details - The Phase 1b/2 study of ADG126 in combination with Merck's KEYTRUDA has shown efficacy at a 10 mg/kg dose, with new data to include results from a 20 mg/kg loading dose followed by 10 mg/kg [2] - The presentation will take place on January 25, 2025, from 7:00 a.m. to 7:55 a.m. Pacific Time at Moscone West, San Francisco, with the abstract number 193 [3] Group 2: Virtual Event Information - A virtual key opinion leader (KOL) event will be hosted on January 25, 2025, featuring experts discussing the treatment landscape for advanced/metastatic MSS CRC and the importance of CTLA-4 targeting [4] Group 3: Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence [5] - The company’s SAFEbody technology aims to improve safety and tolerability of antibody therapeutics by enabling tumor-specific targeting while minimizing off-tumor toxicity [6] - ADG126, the lead clinical program, is a masked anti-CTLA-4 SAFEbody targeting regulatory T cells in the tumor microenvironment, currently in clinical studies for MSS CRC [7]

Core Insights - Adagene Inc. is hosting a virtual key opinion leader (KOL) event on January 25, 2025, to discuss the treatment landscape for advanced/metastatic microsatellite-stable (MSS) colorectal cancer (CRC) and the importance of CTLA-4 targeting for durable responses [1] - The event will provide updates on the Phase 1b/2 study of ADG126 (muzastotug) in combination with KEYTRUDA (pembrolizumab) for advanced/metastatic MSS CRC, which will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium [2] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using computational biology and artificial intelligence [8] - The company’s SAFEbody technology aims to improve safety and tolerability of antibody therapeutics by utilizing precision masking to target tumors while minimizing toxicity to healthy tissues [9] - Adagene's lead clinical program, ADG126, is a masked anti-CTLA-4 SAFEbody currently in Phase 1b/2 studies, specifically targeting MSS colorectal cancer [10] Key Opinion Leaders - Aurélien Marabelle, MD, PhD, is an expert in oncology and immunology, leading early-phase clinical trials of cancer immunotherapies and has published over 280 peer-reviewed articles [4] - Daneng Li, MD, focuses on gastrointestinal malignancies and the development of novel therapeutics, with a strong background in medical oncology [5] - Marwan Fakih, MD, has extensive experience in gastrointestinal cancers and has led numerous clinical trials, particularly in colorectal cancer [6][7]

Safety and Efficacy of ADG126 - ADG126 (Muzastotug) demonstrated improved safety and efficacy profiles compared to ipilimumab, driven by precision masking and enhanced antibody-dependent cellular cytotoxicity (ADCC) [1] - The rate of Grade 3 and higher treatment-related adverse events (TRAEs) for ADG126 in combination with pembrolizumab was significantly lower than historically reported rates for other anti-CTLA-4 therapies [6] - Repeat dosing of ADG126 at 10 mg/kg in combination with pembrolizumab showed encouraging clinical efficacy and well-tolerated safety, supporting its potential as a best-in-class anti-CTLA-4 therapy [7] Clinical Trial Results - The clinical trial for ADG126 in combination with pembrolizumab showed durable disease control and early survival benefits in patients with advanced MSS CRC, with a dose-dependent efficacy observed [5] - One patient in the trial experienced an 80% decrease in target lesions after treatment with ADG126 and pembrolizumab, correlating with a 100% decrease in carcinoembryonic antigen (CEA) levels [6] Dosing Regimen and Future Studies - A single dose of ADG126 at 10 mg/kg resulted in a three-fold increase in active drug exposure in tumor tissue compared to ipilimumab at 1 mg/kg, while maintaining similar plasma active drug levels [6] - Adagene is evaluating a new dosing regimen of ADG126 at 20 mg/kg followed by a 10 mg/kg maintenance dose in combination with pembrolizumab, with data expected in 2025 [7] Technology and Platform - The unique epitope of ADG126 allows for cross-reactivity across species, enhancing pharmacokinetic modeling and tumor-specific engagement of CTLA-4 [3] - The ongoing clinical studies validate the SAFEbody platform's applicability to various antibody-based therapeutic modalities, including antibody-drug conjugates [11] - Adagene's SAFEbody technology aims to minimize on-target off-tumor toxicity while enabling tumor-specific targeting in the tumor microenvironment [10]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adagene Inc. Sponsored ADR is one of 1019 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank gau ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adagene Inc. Sponsored ADR is one of 1017 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Ra ...

SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024. The poster will report results of an ongoing phase 1b/2 trial of Adagene's masked anti-CTLA-4 SAFEbody in combination with the anti-PD-1 treatment pembrolizumab. The title is: Increased Therapeuti ...

SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024. The poster will report results of an ongoing phase 1b/2 trial of Adagene’s masked anti-CTLA-4 SAFEbody in combination with the anti-PD-1 treatment pembrolizumab. The title is: Increased Therapeut ...

SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024. Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody® ADG126. Company management will also host investor meetings. Jefferies ...

SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024. Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody® ADG126. Company management will also host investor meetings. Jefferie ...